Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

37
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

26
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes.

Diabetes research and clinical practice·2026
Same author

Sex Differences in Characteristics and Outcomes Among Patients With Hypertrophic Cardiomyopathy: Insights From the REVEAL-HCM Study.

Journal of the American Heart Association·2026
Same author

Sex differences in circulating microRNA profiles in heart failure with preserved and reduced ejection fraction.

European heart journal open·2026
Same author

Changes in the Heart Sounds Between Discharge and Initial Follow-Up and Subsequent Cardiac Events in Patients with Acute Decompensated Heart Failure.

CJC open·2026
Same author

Acute cardiac complication in a patient with antimitochondrial M2 antibody-positive myositis on immunosuppressive therapy.

Journal of cardiology cases·2026
Same author

Restrictive filling pattern of transmitral inflow in acute decompensated heart failure with preserved ejection fraction: insights from the KCHF registry.

Open heart·2026

Related Experiment Video

Updated: Aug 19, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K

Genome Editing and Pathological Cardiac Hypertrophy.

Takao Kato1

  • 1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. tkato75@kuhp.kyoto-u.ac.jp.

Advances in Experimental Medicine and Biology
|December 1, 2022
PubMed
Summary

Genome editing technologies like CRISPR offer potential cures for hereditary heart diseases by correcting genetic defects. While germline editing faces ethical debates, somatic editing shows promise for treating existing cardiomyopathies.

Keywords:
CRISPR/CasDMDGenome editing; HCM

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.4K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.7K

Related Experiment Videos

Last Updated: Aug 19, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.4K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.7K

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Gene Therapy

Background:

  • Hereditary myocardial diseases pose significant health challenges.
  • Genome editing tools are emerging as powerful research and therapeutic modalities.
  • Transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), and CRISPR systems are key technologies.

Purpose of the Study:

  • To review the application of genome editing in studying and treating cardiomyopathies.
  • To discuss the potential of germline and somatic genome editing for cardiovascular diseases.

Main Methods:

  • Review of current literature on genome editing tools (TALENs, ZFNs, CRISPR).
  • Analysis of applications in experimental cardiomyopathy studies.
  • Evaluation of therapeutic potential for hereditary myocardial diseases.

Main Results:

  • Genome editing can permanently eliminate monogenic cardiovascular diseases via germline modification, though ethically complex.
  • Somatic genome editing presents a promising therapeutic strategy for hereditary cardiomyopathies, particularly where gene knockout is beneficial.
  • Technical challenges remain for widespread clinical application of somatic genome editing.

Conclusions:

  • Genome editing holds significant promise for both research and treatment of hypertrophic cardiomyopathy and other cardiomyopathies.
  • Germline editing offers hereditary disease elimination but requires ethical consideration.
  • Somatic editing provides a potential treatment avenue for existing patients, pending technical advancements.